The treatment of Hepatitis C, a viral liver disease affecting ~150 million people globally, has seen some major advances in the last few years. The emergence of several new direct acting antivirals has turned Hepatitis C into a curable condition, offering a shorter duration of treatment with fewer side effects.
These remarkable advances led the World Health Organization (WHO) to include these ground-breaking new treatments for hepatitis C in the latest version of their Essential Medicines List. While the WHO recognizes the value and impact of this new generation of treatments, they emphasized the need for uniform strategies to make these costly medicines more affordable globally.
The WHO’s Essential Medicines List is updated every two years and outlines the most efficacious, safe and cost-effective medicines for priority conditions. This list helps governments around the world determine which treatments they should make available.